Peter Lin MD, CCFP
Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, CanadaDr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.
Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.
Disclosures
Dr. Lin has consulted with the following companies on Continuing Medical Education programs:Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.
No clinical trials. No patents.
Recent Contributions to PracticeUpdate:
- Adverse Cardiac Events in Patients With Chest Pain at Hospital Admission
- Imaging Correlates of Memory and Concussion History in Retired Athletes
- Stroke Prevention in Atrial Fibrillation
- Blood Pressure Control Does Not Prevent Increased Stroke Risk
- Grip Strength Is a Prognostic Indicator of All-Cause and Cardiovascular Mortality
- Effect of Antihypertensive Medications on Falls
- Knowledge of Public Access Defibrillation
- PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?
- Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy
- Chest Pain and Prodromes and the Assessment of Cardiovascular Disease